Syndax Pharmaceuticals In... (SNDX)
15.59
-0.05 (-0.32%)
At close: Mar 03, 2025, 12:17 PM
No 1D chart data available
| Bid | 15.55 |
| Market Cap | 1.33B |
| Revenue (ttm) | 16.52M |
| Net Income (ttm) | -296.8M |
| EPS (ttm) | -3.64 |
| PE Ratio (ttm) | -4.28 |
| Forward PE | -3.8 |
| Analyst | Buy |
| Ask | 15.6 |
| Volume | 1,047,353 |
| Avg. Volume (20D) | 2,468,184 |
| Open | 16.15 |
| Previous Close | 15.64 |
| Day's Range | 14.84 - 16.50 |
| 52-Week Range | 12.06 - 25.16 |
| Beta | 0.90 |
About SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that b...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 2, 2016
Employees 184
Stock Exchange NASDAQ
Ticker Symbol SNDX
Website https://www.syndax.com
Analyst Forecast
According to 10 analyst ratings, the average rating for SNDX stock is "Buy." The 12-month stock price forecast is $37, which is an increase of 137.33% from the latest price.
Buy 90.00%
Hold 10.00%
Sell 0.00%
Earnings Surprise
Syndax Pharmaceuticals has released their quartely earnings
on Mar 3, 2025:
Next Earnings Release
Syndax Pharmaceuticals Inc. is scheduled to release its earnings on Mar 3, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 hours ago
Syndax Pharmaceuticals shares are trading lower af...
Unlock content with
Pro Subscription
3 months ago
-25.57%
Syndax Pharmaceuticals shares are trading lower. The company announced topline results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the Phase 2 portion of the AUGMENT-101 trial of revumenib.
